Safety and Immunogenicity of Novel Vaccination Schedules With Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP

University of Oxford

Status and phase: Completed; Phase 1

Conditions: Malaria

Treatments: Biological: Vaccination Schedule Two; Biological: Vaccination Schedule Five; Biological: Vaccination Schedule Six; Biological: Vaccination Schedule Four; Biological: Vaccination Schedule Three; Biological: Vaccination Schedule One; Biological: Vaccination Schedule Seven

Study type: Interventional

Funder types: Other

Identifiers

NCT01364883

VAC043

Details and patient eligibility

About

This is an open label phase I study, to assess the safety and immunogenicity of novel schedules for vaccination with the candidate malaria vaccines AdCh63 ME-TRAP and MVA ME-TRAP. These vaccines have been evaluated previously in a number of clinical trials proved to be safe and capable of inducing protective cellular immune response following challenge with the parasite. All volunteers recruited will be healthy adults. They will be primed with AdCh63 ME-TRAP administered intramuscularly and boosted several times with AdCh63 ME-TRAP and MVA ME-TRAP according to various schedules.. Safety data will be collected for each of the seven regimens. Secondary aims of this study will be to assess the immune responses generated by each of these regimes.

Enrollment: 39 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy adults aged 18 to 50 years
• Able and willing (in the Investigator's opinion) to comply with all study requirements
• Willing to allow the investigators to discuss their medical history with their General Practitioner
• For female volunteers, willingness to practice continuous effective contraception during the study
• Agreement to refrain from blood donation during the course of the study
• Written informed consent

Exclusion criteria

• Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use during the study period
• Prior receipt of an investigational malaria vaccine or any other investigational vaccine likely to impact on interpretation of the trial data
• Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
• Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)
• Pregnancy, lactation, or intention to become pregnant during the study
• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products, Kathon History of clinically significant contact dermatitis
• Any history of anaphylaxis in relation to vaccination
• Any history of malaria Travel to a malaria endemic region during the study period or within the six months preceding enrolment in the study
• History of serious psychiatric condition that may affect participation in the study
• Any other serious chronic illness requiring hospital specialist supervision -Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week
• Suspected or known injecting drug abuse in the five years preceding enrolment -Seropositive for hepatitis B surface antigen (HBsAg)
• Seropositive for hepatitis C virus (antibodies to HCV)
• Any relevant history of cancer (excludes basal cell carcinoma of the skin and cervical carcinoma in situ)
• Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis
• Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of study data

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

39 participants in 7 patient groups

Group 1

Experimental group

Description:

AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16

Treatment:

Biological: Vaccination Schedule One

Group 2

Experimental group

Description:

AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16, MVA ME-TRAP boost W24

Treatment:

Biological: Vaccination Schedule Two

Group 3

Experimental group

Description:

AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W4, MVA ME-TRAP boost W8, MVA ME-TRAP boost W12

Treatment:

Biological: Vaccination Schedule Three

Group 4

Experimental group

Description:

AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W8, MVA ME-TRAP boost W16, MVA ME-TRAP boost W24

Treatment:

Biological: Vaccination Schedule Four

Group 5

Experimental group

Description:

AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16

Treatment:

Biological: Vaccination Schedule Five

Group 6

Experimental group

Description:

AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W12

Treatment:

Biological: Vaccination Schedule Six

Group 7

Experimental group

Description:

AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24

Treatment:

Biological: Vaccination Schedule Seven